Establishment and Validation of a Non-Invasive Diagnostic Nomogram to Identify Spontaneous Bacterial Peritonitis in Patients With Decompensated Cirrhosis

Shoushu Xiang 1†, Juntao Tan 2†, Chao Tan 3, Qian Xu 1, Yuanjiu Wen 4, Tiantian Wang 1, Chen Yang 5 and Wenlong Zhao 1,5*

1 College of Medical Informatics, Chongqing Medical University, Chongqing, China, 2 Department of Medical Administration, People’s Hospital of Chongqing Banan District, Chongqing, China, 3 Cancer Hospital, Chongqing University, Chongqing, China, 4 Department of General Medicine, Army Medical University (Third Military Medical University), Chongqing, China, 5 Medical Data Science Academy, Chongqing Medical University, Chongqing, China

Background: Spontaneous bacterial peritonitis (SBP) is a common and life-threatening infection in patients with decompensated cirrhosis (DC), and it is accompanied with high mortality and morbidity. However, early diagnosis of spontaneous bacterial peritonitis (SBP) is not possible because of the lack of typical symptoms or the low patient compliance and positivity rate of the ascites puncture test. We aimed to establish and validate a non-invasive diagnostic nomogram to identify SBP in patients with DC.

Method: Data were collected from 4,607 patients with DC from July 2015 to December 2019 in two tertiary hospitals in Chongqing, China (A and B). Patients with DC were divided into the SBP group (995 cases) and the non-SBP group (3,612 cases) depending on whether the patients had SBP during hospitalization. About 70% (2,685 cases) of patients in hospital A were randomly selected as the training data, and the remaining 30% (1,152 cases) were used as the internal validation set. Patients in hospital B (770 cases) were used as the external validation set. The univariate analysis and least absolute shrinkage and selection operator (LASSO) regression were used to screen variables, and logistic regression was used to determine independent predictors to construct a nomogram to identify patients with SBP. Area under curve (AUC), calibration curve, and dynamic component analysis (DCA) were carried out to determine the effectiveness of the nomogram.

Result: The nomogram was composed of seven variables, namely, mean red blood cell hemoglobin concentration (odds ratio [OR] = 1.010, 95% CI: 1.004–1.016), prothrombin time (OR = 1.038, 95% CI: 1.015–1.063), lymphocyte percentage (OR = 0.955, 95% CI: 0.943–0.967), prealbumin (OR = 0.990, 95% CI: 0.987–0.993), total bilirubin (OR = 1.003 95% CI: 1.002–1.004), abnormal C-reactive protein (CRP) level (OR = 1.395, 95% CI: 1.107–1.755), and abnormal procalcitonin levels (OR = 1.975 95% CI: 1.522–2.556). Good discrimination of the model was observed in the internal and external validation sets (AUC = 0.800 and 0.745, respectively). The calibration curve result indicated that
INTRODUCTION
Liver cirrhosis (LC) results from different mechanisms of liver injury that lead to necroinflammation and fibrogenesis. Histologically, it is characterized by diffuse nodular regeneration surrounded by dense fibrotic septa with subsequent parenchymal extinction and collapse of liver structures, together causing pronounced distortion of hepatic vascular architecture (1–3). LC is responsible for increased morbidity and mortality in developed countries; it is the 14th most common cause of death in adults worldwide but the fourth in Central Europe. It causes 1.03 million deaths worldwide every year (4). About 1,70,000 individuals die from LC per year in Europe (5), whereas 33,539 die from LC annually in the United States (6). LC is divided into compensated asymptomatic cirrhosis and decompensated cirrhosis (DC). The transition from compensated asymptomatic cirrhosis to DC occurs at a rate of about 5–7% per year (7). DC is a systemic disease with multiple organ or system dysfunction (8). Patients with DC are prone to hypersplenism and decreased immune function, and they lack resistance to endogenous and exogenous bacteria. Thus, patients with DC are prone to infection of various parts and tissues.

A particular threat for patients with DC is the development of bacterial infections (9). Patients with DC may suffer from significant alterations in various parts of the immune system, which can cause complex cirrhosis-associated immune dysfunction (10). As a result, these patients have a higher susceptibility for infections but show a hyperinflammatory response as soon as an infection has been acquired. The most frequent type of infection in patients with DC is spontaneous bacterial peritonitis (SBP) (11, 12).

Spontaneous bacterial peritonitis is acute bacterial peritonitis caused by non-abdominal organ infection. Given that ascites is a good culture medium for bacteria, patients with cirrhosis are prone to SBP after ascites. SBP is a serious complication of advanced liver disease and chronic severe hepatitis, with a prevalence of 10–30% among hospitalized patients (10, 13). Different investigations reported varying hospital mortality rates in hospitalized patients with cirrhosis and SBP (20–40%) (14–17). SBP worsens the outcomes of chronic liver diseases and increases the risk of complications, such as renal and hepatic failure and portal hypertension (18, 19). SBP diagnosis follows the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases guidelines, which indicate that ascites polymorphonuclear leukocyte counts combined with no intra-abdominal source of infection are suggestive of SBP (20, 21). However, ascites puncture is an invasive procedure, in which patient compliance is poor and the examination is time-consuming (24–48 h). The positive rate is as low as 35–65% (22). In some special cases, the patient’s physical condition cannot carry out ascites puncture. On the basis of the current diagnostic strategies, many SBP cases can be misdiagnosed, leading to a delay in treatment or antibiotic abuse. Moreover, early clinical diagnosis of SBP is difficult because of its atypical clinical manifestations, few symptoms, or common symptoms, and signs of other diseases.

Although many studies have discussed the morbidity, diagnosis, and treatment of SBP, its early diagnosis still presents some difficulties. Currently, many risk factors and diagnostic studies of DC based on clinically recognized risk factors are small-sample studies. The model has not been further verified, and the availability and accuracy of the model in clinical use cannot be guaranteed. The clinical factors involved in the study are non-clinical common factors, in daily monitoring, doctors or nurses cannot be reminded of the risk of early detection of SBP. The study design has few clinical factors, strong intervenability and is easily affected by a single influencing factor. This study aimed to establish a simple and effective method for diagnosing whether SBP occurs in patients with DC based on large samples and common clinical indicators of DC. In this study, a nomogram was employed. In addition, we developed an online application based on the nomogram to diagnose SBP in patients with DC. This work can be used to clinically evaluate patients with DC to assess the risk of SBP.

MATERIALS AND METHODS
Study Subjects
This study is a retrospective review. We collected data from 4,607 patients diagnosed with DC in A hospital (3,612 cases) and B hospital (770 cases) in the Big Data Platform of Medical Data Research Institute of Chongqing Medical University between July 2015 and December 2019.

The inclusion criterion was a diagnosis of DC between July 2015 and December 2019. Exclusion criteria were as follows: patients younger than 18 years old; patients suffering from acquired immunodeficiency syndrome; patients suffering from tumors; patients with secondary peritonitis; patients with tuberculous peritonitis; and indicators with a missing rate > 30%.

The diagnosis of DC is based on LC, with complications of portal hypertension and (or) liver dysfunction. There is a basis for the diagnosis of LC: the diagnosis of LC is confirmed by liver biopsy, clinical, biochemical, and imaging data or past

the nomogram was well-calibrated. The DCA curve of the nomogram presented good clinical application ability.

**Conclusion:** This study identified the independent risk factors of SBP in patients with DC and used them to construct a nomogram, which may provide clinical reference information for the diagnosis of SBP in patients with DC.

**Keywords:** decompensated cirrhosis, spontaneous bacterial peritonitis, nomogram, diagnostic, non-invasive
| Variable                  | Total (n = 3,837) | SBP (n = 796) | Non-SBP (n = 3,041) | Z/χ²  | P     |
|---------------------------|-------------------|---------------|---------------------|-------|-------|
| Sex (Male)                | 2,587 (67.42%)    | 599 (75.25%)  | 1,988 (65.37%)      | 28.02 | <0.001|
| Hypertension (Yes)        | 497 (12.95%)      | 80 (10.05%)   | 417 (13.71%)        | 7.505 | 0.006 |
| Diabetes (Yes)            | 743 (19.36%)      | 134 (16.83%)  | 609 (20.03%)        | 4.117 | 0.042 |
| HE (Yes)                  | 361 (9.41%)       | 131 (16.46%)  | 230 (7.56%)         | 58.55 | <0.001|
| UGIB (Yes)                | 1,211 (31.56%)    | 181 (22.74%)  | 1,030 (33.87%)      | 36.192| <0.001|
| Hypoproteinemia (Yes)     | 452 (11.78%)      | 138 (17.34%)  | 314 (10.33%)        | 29.84 | <0.001|
| Hypersplenism (Yes)       | 826 (21.53%)      | 138 (17.34%)  | 688 (22.62%)        | 10.441| 0.004 |
| EGVB (Yes)                | 1,394 (36.33%)    | 198 (24.87%)  | 1,196 (39.33%)      | 56.985| <0.001|
| Hepatitis B               | 2,168 (56.50%)    | 510 (64.07%)  | 1,658 (54.52%)      | 23.405| <0.001|
| Alcoholic liver           | 837 (21.81%)      | 216 (27.14%)  | 621 (20.42%)        | 16.678| <0.001|
| Biliary hepatitis         | 362 (9.43%)       | 54 (6.78%)    | 308 (10.13%)        | 8.258 | 0.004 |
| Hepatitis C               | 271 (7.06%)       | 40 (5.03%)    | 231 (7.60%)         | 6.353 | 0.012 |
| Autoimmune hepatitis      | 279 (7.27%)       | 38 (4.77%)    | 241 (7.93%)         | 9.291 | 0.002 |
| Smoking (Yes)             | 1,811 (47.20%)    | 438 (55.03%)  | 1,373 (45.15%)      | 24.688| <0.001|
| Drinking (Yes)            | 1,809 (47.15%)    | 430 (54.02%)  | 1,379 (45.35%)      | 19.045| <0.001|
| PCT (Abnormal)            | 729 (19.00%)      | 355 (44.60%)  | 374 (12.30%)        | 427.663| <0.001|
| CRP (Abnormal)            | 1,376 (35.86%)    | 452 (56.78%)  | 924 (30.38%)        | 191.149| <0.001|
| Age (Year)                | 53.00 (46.00, 63.00) | 52.00 (45.00, 62.00) | 54.00 (46.00, 3.00) | 15.564| <0.001|
| HD (Days)                 | 10.00 (6.00, 17.00) | 15.00 (9.00, 22.00) | 9.00 (6.00, 15.00) | −13.404| <0.001|
| NE (%)                    | 68.00 (59.00, 76.40) | 74.00 (66.20, 81.91) | 66.30 (57.40, 74.50) | −15.564| <0.001|
| NE (×10^9/L)              | 2.72 (1.79, 4.23) | 3.94 (2.60, 6.53) | 2.49 (1.66, 3.74) | −17.308| <0.001|
| MCV (IL)                  | 91.50 (85.10, 97.00) | 92.00 (85.33, 98.60) | 91.30 (85.00, 96.60) | −3.141| 0.002 |
| MCH (pg)                  | 31.00 (27.90, 33.10) | 31.90 (29.43, 34.00) | 30.70 (27.60, 32.90) | −8.412| <0.001|
| MCHC (g/L)                | 336.00 (321.00, 347.00) | 343.50 (329.00, 356.00) | 333.00 (319.00, 345.00) | −12.884| <0.001|
| LY% (%)                   | 21.00 (14.22, 28.80) | 15.46 (10.30, 21.40) | 22.60 (15.70, 30.10) | −16.953| <0.001|
| LY (×10^9/L)              | 0.85 (0.57, 1.25) | 0.83 (0.56, 1.26) | 0.85 (0.58, 1.25) | −0.922| 0.357 |
| WBC (×10^9/L)             | 4.22 (3.00, 6.10) | 5.49 (3.86, 8.59) | 3.99 (2.85, 5.53) | −14.735| <0.001|
| Red blood cell count (×10^9/L) | 3.49 (2.88, 4.04) | 3.38 (2.78, 3.93) | 3.51 (2.92, 4.07) | −3.92 | <0.001|
| PLT (×10^9/L)             | 70.00 (46.00, 110.75) | 73.00 (47.00, 117.75) | 69.00 (46.00, 109.00) | −1.691| 0.091 |
| Hb (g/L)                  | 104.00 (84.00, 123.00) | 104.00 (84.00, 123.00) | 103.00 (84.00, 123.00) | −0.119| 0.906 |
| Calcium (mmol/L)          | 2.10 (1.99, 2.21) | 2.04 (1.95, 2.16) | 2.12 (2.01, 2.22) | −9.984| <0.001|
| Phosphorus (mmol/L)       | 1.05 (0.90, 1.20) | 1.03 (0.87, 1.18) | 1.05 (0.91, 1.20) | −2.676| 0.007 |
| Magnesium (mmol/L)        | 0.78 (0.71, 0.85) | 0.78 (0.70, 0.86) | 0.78 (0.71, 0.85) | −0.741| 0.459 |
| Potassium (mmol/L)        | 3.89 (3.59, 4.21) | 3.88 (3.54, 4.26) | 3.89 (3.60, 4.20) | −0.091| 0.928 |
| Sodium (mmol/L)           | 139.00 (136.00, 141.40) | 138.52 (135.30, 141.00) | 139.10 (136.00, 141.50) | −3.486| <0.001|
| Chlorine (mmol/L)         | 102.80 (99.20, 106.70) | 102.30 (98.30, 105.30) | 103.00 (99.40, 105.80) | −3.865| <0.001|
TABLE 1 | Continued

| Variable                  | Total (n = 3,837) | SBP (n = 796) | Non-SBP (n = 5,041) | Z/χ² | P     |
|---------------------------|-------------------|---------------|--------------------|------|-------|
| Albumin (g/L)             | 31.40 (28.30, 35.40) | 31.20 (28.25, 35.20) | 31.50 (28.30, 35.50) | −0.98 | 0.327 |
| Total bilirubin(umol/L)   | 27.80 (17.00, 13.83, 86.50) | 70.90 (27.50, 26.75, 161.70) | 24.80 (15.70, 12.00, 69.10) | −19.89 | <0.001 |
| Urea(mmol/L)              | 5.30 (4.09, 7.19) | 5.68 (4.14, 8.21) | 5.21 (4.08, 7.03) | −3.864 | <0.001 |
| Uric acid(umol/L)         | 288.35 (213.73, 375.08) | 263.85 (170.95, 375.58) | 293.55 (224.33, 375.58) | −5.925 | <0.001 |
| Creatinine (umol/L)       | 67.00 (55.50, 84.50) | 67.00 (54.85, 83.90) | 67.00 (55.60, 83.90) | −0.288 | 0.773 |
| ALP (IU/L)                | 115.00 (83.00, 161.00) | 124.00 (90.00, 167.50) | 112.00 (81.00, 158.00) | −4.28 | <0.001 |
| GGT (IU/L)                | 52.00 (28.00, 111.00) | 60.00 (31.00, 110.00) | 50.00 (27.00, 110.00) | −3.275 | 0.001 |
| ALT                       | 30.00 (19.00, 54.79) | 39.00 (22.00, 118.00) | 28.00 (19.00, 48.00) | −9.899 | <0.001 |
| PAB (mg/L)                | 80.00 (51.00, 123.00) | 52.00 (34.50, 78.00) | 88.00 (58.00, 132.00) | −20.046 | <0.001 |
| PT(S)                     | 16.70 (15.10, 19.50) | 19.60 (16.73, 24.40) | 16.30 (14.80, 18.50) | −19.734 | <0.001 |
| INR                       | 1.36 (1.19, 1.65) | 1.67 (1.36, 2.21) | 1.31 (1.16, 1.54) | −19.783 | <0.001 |
| MELD                      | 11.27 (8.02, 16.52) | 17.24 (10.73, 24.08) | 10.49 (7.57, 14.59) | −18.903 | <0.001 |
| Total protein(g/L)        | 66.10 (59.53, 72.80) | 62.60 (56.70, 68.30) | 67.10 (60.40, 73.70) | −11.287 | <0.001 |

HE, hepatic encephalopathy; UGIB, upper gastrointestinal bleeding; EGVWB, esophageal and gastric varices without bleeding; PCT, Procalcitonin; CRP, C-reactive protein; HD, hospitalization days; NE%, percentage of neutrophils; NE, the absolute number of neutrophils; MCV, mean corpuscular volume; MCH, mean corpuscular volume; MCHC, mean red blood cell hemoglobin concentration; LY%, lymphocyte percentage; LY, lymphocyte count; WBC, white blood cell count; PLT, platelet count; Hb, hemoglobin concentration; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; ALT, alanine aminotransferase; PAB, prealbumin; PT, prothrombin time; INR, international normalized ratio; MELD, a model for end-stage liver disease.

FIGURE 1 | Demographic and clinical feature selection using the LASSO binary logistic regression model. (A) The selection of the best parameter (lambda) in the LASSO model uses five-fold cross-validation with the lowest standard. The relationship curve between partial likelihood deviation (binomial deviation) and log(lambdawas plotted. Dotted vertical lines were drawn at the optimal values by using the minimum criteria and the 1 SE of the minimum criteria (the 1-SE criteria). (B) LASSO coefficient profiles of the 11 features. A coefficient profile plot was produced against the log (lambda) sequence. Vertical line was drawn at the value selected using five-fold cross-validation. LASSO, least absolute shrinkage and selection operator; SE, standard error.
medical records, and the diagnosis is in accordance with the “Chinese guidelines on the management of liver cirrhosis” (23). The portal hypertension-related complications and symptoms include ascites, bleeding from esophageal gastric varices, sepsis, hepatic encephalopathy, and hepatorenal syndrome. The diagnostic criteria of SBP are based on the 2010 “European Society of Liver Diseases Cirrhosis and Ascites, SBP Guidelines” (24), which involve any two of the following indicators: clinical manifestations of fever, abdominal pain, abdominal tenderness, rebound pain, and other abdominal cavity symptoms and signs of internal infection; routine examination of ascites for white blood cells $>0.5 \times 10^9/L$ and neutrophils $>0.25 \times 10^9/L$; and positive bacterial culture of ascites.

**Demographic Features and Clinical Characteristics**

This study included common clinical indicators of patients with LC by consulting clinical experts and inquiring about the related literature. Etiology of LC: hepatitis B, hepatitis C, alcoholic liver, biliary hepatitis, and autoimmune hepatitis. Common complications of patients with SBP: upper gastrointestinal bleeding and hepatic encephalopathy. Laboratory data: blood routine, liver function, renal function, electrolytes, blood coagulation function indexes, and model foe end stage liver disease (MELD). Basic information and medical history information: age, sex, smoking history, drinking history, high blood pressure, and diabetes. C-reactive protein (CRP) $>8$ mg/L is defined as abnormal CRP, whereas procalcitonin $>0.5 \mu$g/L is defined as abnormal procalcitonin.

**Statistical Analysis**

We collected 3,873 patients with DC, including 1,286 female patients and 2,587 male patients. In the first step, we used SPSS24.0 to perform single-factor analysis on the SBP group and non-SBP group, and the test standard was set to $p < 0.05$. The enumeration data were expressed by rate and percentage, and the chi-square test was used for comparison between groups. All the quantitative variables do not obey the normal distribution. Those were represented by median and interquartile range (IQR) $[\text{M(Q25–Q75)}]$, and comparison between groups was represented by the Mann–Whitney U-test. We use Originlab to draw stacked histograms of antibiotic usage. In the second step, with the aid of R software (version 3.6.2; https://www.R-project.org), we randomly divided the patients into two groups, namely, traindata ($n = 2,685$) and internal validation set ($n = 1,152$), according to a theoretical ratio of 7:3. In the third step, we adopted the least absolute shrinkage and selection operator (LASSO) regression method to analyze variables. LASSO was applied for data dimensionality reduction. The LASSO regression model employs a double-standard error by constructing a penalty function. Concerning the characteristics of this method, we screened suitable and effective risk factors for patients with DC and SBP in LASSO regression analysis and selected nine characteristic factors. Variables selected through logistic regression analysis were considered for odds ratio (OR) and $p$ with 95% CI, and the statistical significance levels were all two-sided. On the basis of the logistic regression results, we selected risk factors with $p < 0.05$ and constructed a nomogram prediction model. In this study, seven variables were selected. For the validation of the model, we calculated C index, receiver operating characteristic (ROC) curve, and dynamic component analysis (DCA) (22).

**RESULT**

**Baseline Characteristics**

A total of 3,873 patients were included for analyses. The baseline data of enrolled patients are summarized in Table 1. In patients with DC, the prevalence of SBP was 20.75%. The total cohort comprised 2,587 (67.42%) men, and the proportion of men in patients with SBP was high, i.e., 599 men (75.25%). Among all enrolled patients with DC, the median age was 53 years. In terms of suffering from underlying diseases, the proportions of hypertension and diabetes were 12.95 and 19.36%, respectively. This study included five common complications associated with DC, and the incidence of the five common complications is as follow: esophageal and gastric varices without bleeding (36.33%), upper gastrointestinal bleeding (31.56%), hypersplenism (21.53%), hypoproteinemia (11.78%), and hepatic encephalopathy (9.41%). Hepatitis B was the leading etiology of LC (56.50%). The rates of smoking and drinking were 47.20 and 47.15%, respectively.

The percentages of abnormal CRP level and procalcitonin in patients with SBP were 56.78 and 30.38%, respectively, or 44.60 and 12.30%, respectively, compared with those without SBP. The median hospitalization time was 15 days (9, 22) in patients with SBP and 9 days (6, 15) in those without SBP. The median total bilirubin content was 70.90 $\mu$mol/L (27.50, 231.35) in patients with SBP and 24.80 $\mu$mol/L (15.70, 45.80) in those without SBP. The median prothrombin time and international normalized ratio levels of patients with DC and SBP were 19.60 s (16.73, 24.40) and 1.67 (1.36, 2.21), respectively, whereas those of patients without SBP were 16.30 s (14.80, 18.50) and 1.31 (1.16, 1.54). The median MELD level of patients with DC and SBP was 17.24 (10.73, 24.06), whereas that of patients without SBP was 10.49 (7.57, 14.59). Meanwhile, we listed the use of antibiotics in the SBP and non-SBP groups (Supplementary Tables 1, 2 for details).

**Univariate Analysis and LASSO Regression**

A total of 50 indicators were included in this study, and seven indicators were not statistically significant after univariate analysis. For example, no statistical significance was found between patients with SBP and patients without SBP in lymphocyte count, platelet count, hemoglobin concentration, magnesium ion concentration, potassium ion concentration, albumin concentration, and creatinine concentration ($p > 0.05$). The remaining variables were statistically significant, such as CRP level, procalcitonin level, length of hospital stay, calcium concentration, prothrombin time, and MELD score ($p < 0.05$). The analysis results are shown in Table 1.

The least absolute shrinkage and selection operator regression analysis requires consistent initial estimation of regression
The diagnostic nomogram that integrated seven selected features (Figures 1A, B) thereby consolidating our model. The nine predictors were CRP level, absolute neutrophil count, mean red blood cell hemoglobin concentration, lymphocyte percentage, total bilirubin, prealbumin, prothrombin time, procalcitonin level, and MELD (Table 2).

**Development of a Nomogram**

The nine variables of LASSO regression were brought into a multivariate logistic regression, and stepwise logistic regression based on the AIC criterion was performed by step() function. The values of $p$ of seven risk characteristic factors were proven to be significant in the model (Table 3).

The diagnostic nomogram that integrated seven selected features ($p < 0.05$) for the incidence of SBP in the training cohort is shown in Figure 2A. The values of each risk factor were assigned a score on the point scale axis. By adding each single score and using that value in the total point scale axis, the total score could be easily calculated to the probability of SBP. For the convenience of clinicians, we have provided the nomogram as a web-based calculator tool (https://cqmluxs.shinyapps.io/dynnomappdc_and_sbp/). Doctors can enter the indicators for each patient to automatically calculate the patient's probability of SBP.

If the subject had an abnormal CRP level, a normal procalcitonin level, mean red blood cell hemoglobin concentration of 353 g/L, a lymphocyte percentage of 14.92%, a total bilirubin count of 27.1 $\mu$mol/L, a prealbumin count of 171 mg/L, and a prothrombin time of 14.9 s, then the probability of SBP was estimated to be 10.5%.

### Verification of the Nomogram

Good discrimination was obtained by validating the model using internal and external validation sets. In the internal verification set, the AUC was 0.800 and the best cutoff point for the model was $-1.514$, where the specificity was 72.9% and the sensitivity was 75.5% (Figure 3A). In the external verification set, the AUC was 0.745 and the best cutoff point for the model was $-1.351$, where the specificity was 62.2% and the sensitivity was 73.9% (Figure 3B).

In this study, the bootstrap resampling method was used to calibrate the calibration curve of the logistic model (Figure 4A). The diagonal line represents the reference line where the predicted value and the actual value are completely coincident, and the apparent dotted line represents the actual situation of the prediction model. The bias-corrected solid line represents the actual situation of the corrected prediction model. The C-index and Brier score were 0.830 (95% CI: 0.811–0.849) and 0.117 (95% CI: 0.109–0.126), respectively. We compared the nomogram and Child-plug based on DCA. DCA visually showed that the nomogram had a superior overall net benefit within the wide and practical ranges of threshold probabilities. It further indicated that our nomogram conferred significantly high clinical net benefit, which is of great value for the accurate individualized assessment of the incidence of SBP (Figure 4B). These values suggested that the diagnostic model demonstrated good performance.

### DISCUSSION

Spontaneous bacterial peritonitis is a serious threat to the quality of life and survival time of patients with DC. Early detection of the risk of SBP in patients with DC is helpful to improve the quality of life of patients. The survival time of patients can be prolonged, and antibiotics can be better managed and utilized. In this study, we found that mean red blood cell hemoglobin concentration ($OR = 1.010$, 95% CI: 1.004–1.016), prothrombin time ($OR = 1.038$, 95% CI: 1.0151.063), lymphocyte percentage ($OR = 0.955$, 95% CI: 0.943–0.967), prealbumin ($OR = 0.990$, 95% CI: 0.987–0.993), total bilirubin ($OR = 1.003$ 95% CI: 1.002–1.004), abnormal CRP level ($OR = 1.395$, 95% CI: 1.107–1.755), and abnormal procalcitonin levels ($OR = 1.975$, 95% CI: 1.522–2.556) were associated with a higher incidence of SBP. Furthermore, we developed an effective prognostic nomogram composed of seven features. The nomogram had significantly high sensitivity and specificity to distinguish individuals with SBP from DC. DCA further indicated that our nomogram conferred significantly high clinical net benefit, which is of great value for the accurate individualized assessment of the occurrence of SBP.
Several studies have shown that patients with SBP have higher CRP levels than patients without SBP (26–29). In this study, patients with SBP and abnormal CRP levels accounted for 56.78%, which was significantly higher than patients with non-SBP 30.38%, consistent with previous studies. After trauma and infection, CRP increased significantly, and its application in disease diagnosis can assist in judging whether patients have an inflammatory reaction and bacterial infection. After SBP in patients with DC, patients usually have an acute inflammatory response. The level of CRP significantly increases.
In addition, studies have shown that elevated CRP levels are helpful in diagnosing SBP (30–32). Procalcitonin is a precursor of calcitonin that is normally secreted by the C cells of the thyroid gland in healthy individuals. In the absence of infection, extra-thyroid expression of the procalcitonin gene is suppressed in liver, lung, kidney, adrenal tissue, monocytes, granulocytes, testis, prostate, and small intestine (33). Bacterial infection induces a general increase in procalcitonin gene expression, resulting in the constitutive release of procalcitonin from parenchymal tissue throughout the body. Procalcitonin is significantly elevated during the systemic response to infection, and this effect can be detected 2-4 h after the inflammatory response; it is known as a new inflammatory biomarker of bacterial infection (34–36). Su DH, Connert S, Cekin Y, et al. have shown that procalcitonin is a marker of inflammation for the diagnosis of SBP and can be used by clinicians as an aid in the rapid and accurate diagnosis of SBP (37–39).

The liver can synthesize all coagulation factors and fibrinolytic factors except tissue factors and calcium ions. The coagulation factor is the most sensitive indicator to evaluate the status of liver function. Measuring the level of coagulation factor can quickly reflect the status of liver function. Prolonged prothrombin time indicates decreased liver function, and SBP should be considered when prolonged prothrombin time occurs. Many scholars have reported that total bilirubin is an independent risk factor for cirrhosis patients complicated with SBP (40–42). The increase in total bilirubin reflects the situation of liver damage and the decline of liver synthetic function. Total bilirubinostasis can damage the function of Kupffer cells and aggravate liver function damage; it is accompanied by a significant decline in the function of the monocyte-macrophage system. It can easily lead to bacterial migration and bacteremia, which can increase the possibility of SBP. The occurrence of SBP further increases the burden on the liver. Given their interaction, patients with cirrhosis with significantly increased total bilirubin levels need to be highly alert to the occurrence of SBP.

Prealbumin is an acute-phase protein with a relative molecular weight of 55 kDa. It participates in immune regulation and plays a role in maintaining the acid-base balance. Li Wq (3) pointed out that the distribution rate of serum albumin from intravascular to extravascular increases significantly during an infection, and the decomposition rate of albumin also increases significantly. Under physiological conditions, prealbumin is mainly present in serum and cerebrospinal fluid and has a shorter half-life (1.9 days) than albumin (43). The short-term increase and decrease are more obvious. The detection of serum prealbumin level has important clinical value in the diagnosis, treatment, and prognosis of various liver diseases, such as DC (44). Early diagnosis has higher sensitivity in predicting the occurrence of SBP in patients with cirrhosis. We found that lymphocyte percentage and mean corpuscular hemoglobin concentration were not discussed in previous study of influencing factors, hoping to provide a conjecture for related researchers.

In this study, the predictors included in the SBP diagnostic model for patients with DC were common clinical factors that could be collected in patients with DC. Thus, the model is useful and applicable in daily practice. Several predictors involved included liver functional indicators and inflammatory indicators, which did not have a major influence on the diagnosis when a single factor was affected. The performance of the model was relatively stable. Compared with previous studies, the online nomograms we provided could help doctors make a quick diagnosis, help patients perform self-screening and provide the possibility of timely diagnosis and treatment of diseases in places where medical technology is backward. The model performs well in internal and external verification, making it applicable to a large number of patient groups.
Our study had some limitations. First, selection bias may exist due to the retrospective nature of the investigation. However, we used a multicenter and relatively large training cohort to build models, which was further subjected to spatial verification. Second, data on social support, level of education, and socioeconomic status were not available. Further research is warranted to explore the impact of these important indicators.

**CONCLUSION**

This study developed and validated a diagnostic model based on common clinical features of patients with DC. This study is helpful for the early detection of patients with SBP, timely provision of reasonable symptomatic treatment, and improvement of quality of life and prognosis of patients with DC. The online nomogram is convenient for clinicians to use and can increase the acceptability of the model.

**DATA AVAILABILITY STATEMENT**

The data analyzed in this study cannot be disclosed due to the privacy of some patients. Requests to access these datasets should be directed to Shoushu Xiang, 718998832@qq.com.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by ChongQing Medical University. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

**REFERENCES**

1. Schuppan D, Afdhal NH. Liver cirrhosis. *Lancet*. (2008) 371:838–51. doi: 10.1016/S0140-6736(08)60383-9
2. Williams, medicine RJC. Sherlock’s disease of the liver and biliary systems. (2011) 11:506. doi: 10.7861/clinmedicine.11-5-506
3. Li W, Wang X, Zhu H. Kinetics of serum albumin in patients with severe sepsis. *Med J PLA*. (2005) 030:978–80.
4. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. (2012) 380:2095–128. doi: 10.1016/S0140-6736(12)61728-0
5. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: A review of available epidemiological data. *J Hepatol*. (2013) 58:593–608. doi: 10.1016/j.jhep.2012.12.005
6. Donna L H. Deaths: preliminary data for 2011. %] National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics. *Vital Stat Rep*. (2012) 61:1–51.
7. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. *J Hepatol*. (2006) 44:217–31. doi: 10.1016/j.jhep.2005.10.013
8. Arroyo V, Garcia-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. *J Hepatol*. (2014) 61:396–407. doi: 10.1016/j.jhep.2014.04.012
9. Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. *J Hepatol*. (2014) 60:1310–24. doi: 10.1016/j.jhep.2014.01.024
10. Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. *J Hepatol*. (2014) 61:1385–96. doi: 10.1016/j.jhep.2014.08.010
11. Moreau R, Jalan R, Gines P, Pavesi M, Morando FJG. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. *Gastroenterology*. (2013) 144. doi: 10.1053/j.gastro.2013.02.042
12. Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. *Hepatology*. (2002) 35:140–8. doi: 10.1033/jhep.2002.30082
13. Bunchorntavakul C, Chamroonkul N, Chavalidhamrong D. Bacterial infections in cirrhosis: A critical review and practical guidance. *World J Hepatol*. (2016) 8:307–21. doi: 10.4254/wjh.v8.i6.307
14. Alexandre dA. Akin criteria as a predictor of mortality in cirrhotic patients after spontaneous bacterial peritonitis. *Ann Hepatol*. (2014) 13:390–5. doi: 10.1016/S1665-2681(19)30870-1
15. Iliaz R, Ozpolat T, Baran B, Demir K, Kaymakoglu S, Besiik F, et al. Predicting mortality in patients with spontaneous bacterial peritonitis using routine inflammatory and biochemical markers. *Eur J Gastroen Hepat*. (2018) 30:786–91. doi: 10.1097/MEG.0000000000001111
16. Schwabl P, Buscics T, Soucek K, Mandorfer M, Bota S, Blacky A, Reiberger T Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. *Liver Int*. (2015) 35:2121–8. doi: 10.1111/liv.12795
17. Terg R, Gadano A, Cartier M, Casciato P, Lucero R, Munoz A, Abecasis R Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. *Liver Int*. (2009) 29:415–9. doi: 10.1111/j.1478-3231.2008.01877.x
18. How J, Azar MM, Meyer JP. Are Nectarines to Blame? A Case Report and Literature Review of Spontaneous Bacterial Peritonitis Due to Listeria monocytogenes. *Conn Med*. (2015) 79:31–6.
19. Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. *Gut*. (2012) 61:297–310. doi: 10.1136/gutjnl-2011-300779

**AUTHOR CONTRIBUTIONS**

SX, JT, and WZ were involved in concept and design. SX, JT, TW, and CY drafted the manuscript. SX and CT performed the statistical analysis. WZ provided administrative, technical, and material support, had full access to all the data in the study, and take responsibility for the integrity of the data and the accuracy of the data analysis and supervision. YW was responsible for clinical consultation. All the authors critically revised the manuscript for important intellectual content, acquisition, analysis, or interpretation of data, and read and approved the final manuscript.

**FUNDING**

This research was funded by the Intelligence Medicine Project of Chongqing Medical University (Grant no. ZHYX2019001).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2021.797363/full#supplementary-material
20. de Mattos AA, Costabeber AM, Lionco LC, Tovo CV. Multi-resistant bacteria in spontaneous bacterial peritonitis: a new step in management? World J Gastroenterol. (2014) 20:14079–86. doi: 10.3748/wjg.v20.i39.14079
21. Wiest R, Lawson M, Geuken M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. (2014) 60:197–209. doi: 10.1016/j.jhep.2013.07.044
22. Shizuma T. Spontaneous bacterial and fungal peritonitis in patients with liver cirrhosis: A literature review. World J Hepatol. (2018) 10:254–66. doi: 10.4254/wjhl.v10.i2.254
23. Xu X, Ding H, Li W, Xu J, Han Y, Jia J, Zhuang H. Chinese guidelines on the management of liver cirrhosis. J Clin Exp Hepatol. (2019) 35:2408–25. doi: 10.3760/cma.j.issn.1007-3418.2019.11.008
24. Gines P, Angeli P, Lenz K, Moller S, Moore K, Moreau R. Liver EAS. Clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. European Association for the Study of the Liver. J Hepatol. (2010) 53:397–417. doi: 10.1016/j.jhep.2010.05.004
25. Phillips J, Bloom J, Yarlagadda V, Schultz L, Gordetsky J, Tanno FY. Rais-Bahrami M. Internal validation and decision curve analysis of a preoperative nomogram predicting a postoperative complication in pheochromocytoma surgery: An international study. Int J Urol. (2020) 27:463–8. doi: 10.1111/iju.14221
26. Yildirim B, Sari R, Isci N. Patients with spontaneous bacterial peritonitis, and malignant and cirrhotic ascites. J Natl Med Assoc. (2005) 97:276–80. doi: 10.1016/j.pajmsnaym.2004.05.010
27. Badawi R, Asghar MN, Abd-Elsalam S, Elshweikh SA, Haydara T, Albawwy SM. Elfert A Amyloid A in serum and ascitic fluid as a novel diagnostic marker of spontaneous bacterial peritonitis antiinflamm antiellergy agents. Med Chem. (2020) 19:140–8. doi: 10.2174/1871523018666190401154447
28. Falletti E, Cmet S, Cussigh AR, Salvador E, Bitetto D, Fornasiere E, Toniutto P. Recurrent and treatment-unresponsive spontaneous bacterial peritonitis worsens survival in decompensated liver cirrhosis. J Clin Exp Hepatol. (2021) 11:334–42. doi: 10.1016/j.jcheh.2020.08.010
29. Preto-Zamperlini M, Farhat SC, Perondi MB, Pestana AP, Cunha PS, Pugliese RR, et al. Elevated C-reactive protein and spontaneous bacterial peritonitis in patients of cirrhosis with ascites. J Clin Exp Hepatol. (2021) 11:352–7. doi: 10.1111/j.1751-2980.2010.00465.x
30. Lu J, Fejfar T, Kreczler T, Musil T, Husova L, Senkyrik M, et al. Spontaneous bacterial peritonitis in the Czech Republic: prevalence and aetiology. Eur J Gastroenterol Hepatol. (2003) 15:739–43. doi: 10.1097/00058016.46867.62
31. Yuan LY, Ke ZQ, Wang M, Li Y. Procalcitonin and C-reactive protein in the diagnosis and prediction of spontaneous bacterial peritonitis associated with chronic severe hepatitis B. Ann Lab Med. (2013) 33:449–54. doi: 10.3343/alm.2013.33.6.449
32. Metwally K, Fouad T, Assem M, Abdelsameea E, Youssef M. Predictors of spontaneous bacterial peritonitis in patients with cirrhotic ascites. J Clin Transl Hepatol. (2018) 6:372–6. doi: 10.14218/JCTH2018.00001
33. Rahimkhani M, Einollahi N, Khavari Daneshvar H, Dasthi N. Survey of serum procalcitonin in cirrhotic patients. Acta Med Iran. (2013) 51:153–6.
34. Bloos F, Reinhart K. Rapid diagnosis of sepsis. Virulence. (2014) 5:154–60. doi: 10.4161/viru.27393
35. Russwurm S, Wiederhold M, Oberhoffer M, Stonans I, Zipfel PF, Reinhart K. Molecular aspects and natural source of procalcitonin. Clin Chem Lab Med. (1999) 37:789–97. doi: 10.1515/CCLM.1999.119
36. Mehánic S, Baljic R. The importance of serum procalcitonin in diagnosis and treatment of serious bacterial infections and sepsis. Mater Sociomed. (2013) 25:277–81. doi: 10.5455/msm.2013.25.277-281
37. Su DH, Zhuo C, Liao K, Cheng WR, Cheng H, Zhao XF. Value of serum procalcitonin levels in predicting spontaneous bacterial peritonitis. Hepatogastroenterology. (2013) 60:641–6.
38. Connert S, Stremmel W, Elsing C. Procalcitonin is a valid marker of infection in decompensated cirrhosis. Z Gastroenterol. (2003) 41:165–70. doi: 10.1055/s-2003-37314
39. Cekin Y, Cekin AH, Duman A, Yilmaz U, Yesil B, Yolcular BO. The Role of Serum Procalcitonin Levels in Predicting Ascitic Fluid Infection in Hospitalized Cirrhotic and Non-cirrhotic Patients. Int J Med Sci. (2013) 10:1367–74. doi: 10.7150/ijms.6014
40. Zhu LC, Xu I, He WH, Wu W, Zhu X, A. quick screening model for symptomatic bacterascites in cirrhosis. Saudi J Gastroenterol. (2016) 22:282–7. doi: 10.4103/1319-3767.187600
41. Shen HX, Lou XP, Chang XW, Zheng X, Du WT, Zhao BB. Nursing DOJWJCJoD Risk factors for spontaneous bacterial peritonitis in cirrhotic patients:A metaanalysis. (2014) 24:1903. doi: 10.11569/wejcd.v24.i12.1903
42. Paul K, Kaur J, Kazal HL. To study the incidence, predictive factors and clinical outcome of spontaneous bacterial peritonitis in patients of cirrhosis with ascites. J Clin Diag Res. (2015) 9:C009–12. doi: 10.7860/JCDR/2015/14855.6191
43. Fei L, Ling YC, Lan Z, Chi C, Xi MCJJJoDD. Model for end-stage liver disease combined with serum prealbumin to predict the prognosis of patients with decompensated liver cirrhosis. (2010) 11:352–7. doi: 10.1111/j.1751-2980.2010.00465.x
44. Tan L, Meng Y, Zeng T, Wang Q, Long T, Wu S, et al. Clinical diagnostic significance of prealbumin, cholinesterase and retinol binding protein in liver cirrhosis combined with encephalopathy. Br J Biomed Sci. (2019) 76:24–8. doi: 10.1080/09674845.2018.1523673

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Xiang, Tan, Tan, Xu, Wen, Wang, Yang and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.